Alzheimer’s occurs when amyloid precursor protein cleaves into smaller clumps called amyloid-beta peptides that collect between neurons in the brain. Some individuals have a variant of APP that protects them from the development of Alzheimer’s, but little is known about the protein and the way it’s processed.
Dr. D’Adamio’s work aims to shed light on APP, which could potentially lead to increased efficacy in Alzheimer’s medications.
Alzheimer’s is a progressive brain disease and likely the most common form of dementia. By age 85 years and older, between 25 and 50 percent of people will exhibit signs of Alzheimer’s disease.
More articles on quality:
New York law ensures hospitals train caregivers before patients go home
Is healing prayer the prevailing form of primary care medicine?
Adverse reactions to antihistamines more common and varied than previously thought
